Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

In a world that's moving faster day by day, these people from around the world spread the same positive message to love ...

GLP-1 drugs like Ozempic are transforming weight loss, but a new UVA study warns they're not improving a critical measure of ...

The persistent threat of reciprocal tariffs from US President Donald Trump has resulted in many trade deals, while the IMF ...

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

Cosmetic surgeons are reporting a growing number of patients with sagging skin and facial hollowing after losing weight with ...

ASX companies such as LTR Pharma are finding smarter ways to stretch the value of existing assets and launch into broader ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Explore the U.S. new F-47 fighter jet and its potential impact on global military balance, including reactions from Russia ...

Novo Nordisk stock (NVO) (DK:NOVO.B) slumped 21.83% to fall to a new three-year low. It was the stock's worst daily loss since a 26.15% fall on Oct. 19, 1987. It's fallen 24.77% over the past two days ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

Seeking Alpha's roundup of statements, announcements and remarks that could impact markets, sectors or individual stocks.